Sandoz Gets New Leader: Is Restructuring Next For Novartis’ Generics Unit?
Executive Summary
Novartis is focusing on operational efficiencies in its Sandoz generics business to address a difficult pricing environment in the U.S
You may also be interested in...
Novartis Seeks To Be Generics “Powerhouse” With Eon, Hexal Acquisitions
Novartis expects the addition of Eon Labs and Hexal AG to its Sandoz division to create a generic drug "powerhouse" that will play a major role in the emerging "authorized" generics and follow-on biologics markets
Novartis Seeks To Be Generics “Powerhouse” With Eon, Hexal Acquisitions
Novartis expects the addition of Eon Labs and Hexal AG to its Sandoz division to create a generic drug "powerhouse" that will play a major role in the emerging "authorized" generics and follow-on biologics markets
Generic Industry Faces Downturn, Sandoz Says; MMA Changes Hurt
The generic industry is facing a "downturn" in the market for products with low barriers to entry, Sandoz CEO Andreas Rummelt said Jan. 20